Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
Status: | Completed |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - 99 |
Updated: | 10/6/2017 |
Start Date: | March 30, 2015 |
End Date: | May 31, 2016 |
Reveal LINQ™ In-Office 2 (RIO 2) Study United States
The primary purpose of the RIO 2 study is to demonstrate that when the Reveal LINQ™
insertable cardiac monitoring (ICM) system that records subcutaneous ECG insertion procedure
performed in the in-office setting is as safe as LINQ™ insertions performed in the
traditional hospital setting (operating room, cardiac catheterization or electrophysiology
(EP) laboratory).
insertable cardiac monitoring (ICM) system that records subcutaneous ECG insertion procedure
performed in the in-office setting is as safe as LINQ™ insertions performed in the
traditional hospital setting (operating room, cardiac catheterization or electrophysiology
(EP) laboratory).
RIO 2 is a two arm, randomized, prospective, un-blinded, multicenter, non-significant risk
study. The primary objective for RIO 2 will be assessed by randomizing subjects to receive
their LINQ™ insertion in the office setting or in the traditional hospital environment.
Moving the LINQ™ insertion procedure to the office setting is not expected to decrease the
complication rate compared to in hospital insertion procedures, however, moving the LINQ™
insertion procedure out of the traditional hospital setting may benefit the patient and
reduce the burden to the healthcare system.
study. The primary objective for RIO 2 will be assessed by randomizing subjects to receive
their LINQ™ insertion in the office setting or in the traditional hospital environment.
Moving the LINQ™ insertion procedure to the office setting is not expected to decrease the
complication rate compared to in hospital insertion procedures, however, moving the LINQ™
insertion procedure out of the traditional hospital setting may benefit the patient and
reduce the burden to the healthcare system.
Inclusion Criteria:
1. Patient is indicated for continuous arrhythmia monitoring with a Reveal LINQ™
Insertable Cardiac Monitor
2. Patient is 18 years of age or older
3. Patient is willing to undergo ICM insertion procedure outside of the cath lab, OR, EP
lab setting with only local anesthetic
4. Patient is willing and able to provide consent and authorize the use and disclosure of
health information
5. Patient is willing and able to comply with the protocol including the required
follow-up
Exclusion Criteria:
1. Patient has unusual thoracic anatomy or scarring at the implant site which may
adversely affect the success of the implant procedure
2. Patient has reduced immune function or is otherwise at high risk for infection per
physician discretion
3. Current therapy with immunosuppressive agents or chronic steroid use e.g. Prednisone
greater than 20mg per day
4. Patient requires hemodialysis
5. Patient with active malignancy or history of chemotherapy or radiation treatment
Patient has had a recent (within 30 days) or an active infection including but not
limited to pneumonia, urinary tract, cellulitis, or bacteremia.
6. Patient has had major surgery (in the past 6 months)
7. Patient has undergone a procedure which required central venous or intraarterial
access (e.g. AF/VT ablation, EP study, coronary angio) within the last 3 months or is
scheduled for such a procedure while enrolled in the study.
8. Prior history of surgical infection, prosthetic device infection, or endovascular
infection, including endocarditis, in the past 12 months.
9. Patient has a central venous port, an atrio-venous fistula, or a prosthetic valve
10. Patient requires conscious or moderate sedation to receive LINQ™
11. Patient is already implanted with a loop recorder
12. Patient is implanted or indicated for implant with a pacemaker, ICD, CRT device
13. Patient is enrolled in another study that could confound the results of this study,
without documented pre-approval from a Medtronic study manager.
14. Patient's life expectancy is less than 6 months
15. Patient is pregnant
We found this trial at
27
sites
1126 North Church Street
Greensboro, North Carolina 27401
Greensboro, North Carolina 27401
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
455 Pinellas Street
Clearwater, Florida 33756
Clearwater, Florida 33756
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
Fort Lauderdale, Florida 33308
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Sentara Norfolk General Hospital Sentara Norfolk General Hospital is recognized as the number one ranked...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials